BioAffinity Technologies (BIAF) announced that the Australian Patent Office has accepted a patent application for the company’s proprietary platform technology for assessing lung health and predicting the likelihood of multiple lung diseases in patients. The patent application covers methods that use flow cytometry combined with fluorescent probes, molecular “tags” that attach to specific cell types, to detect cellular and molecular signatures of multiple lung diseases.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Technologies Secures Australian Patent for Lung Health
- bioAffinity Technologies Advances Non-Invasive Lung Cancer Diagnostic Study
- bioAffinity Technologies Advances Lung Cancer Detection with Innovative Study
- bioAffinity Technologies Presents at CHEST 2025 Conference
- bioAffinity Technologies Secures Patent for Lung Cancer Detection